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ABSTRACT
Emerging evidence indicates that the islet fibrosis is attributable to activation 
of islet stellate cells (ISCs). In the present study, we compared the differences in 
biological activity of ISCs isolated from diabetic db/db and non-diabetic db/m mice, 
and the effects of the regenerating islet-derived protein 1 (Reg1) on ISC function. We 
showed that ISCs isolated from db/db mice were activated more rapidly than those 
from db/m mice during culture. Both Reg1 and its putative receptor exostosin-like 
glycosyltransferase 3 (EXTL3) were highly expressed by diabetic ISCs. Treatment 
with Reg1 inhibited migration, viability, and synthesis and secretion of Type I 
Collagen(Col-I), Type III Collagen(Col-III) and Fibronectin(FN) by diabetic ISCs, 
and this was associated with deactivation of the PI3K/Akt, MAPK/Erk1/2 signaling 
pathway in an EXTL3-dependent manner. In conclusion, our observations (i) confirmed 
the presence of fibrogenic stellate cells within pancreatic islets, which are prone to be 
activated in Type 2 diabetes, and (ii) revealed a potential role for Reg1 in preventing 
ISC activation.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a common group 
of metabolic disorders characterized by hyperglycemia, 
insulin resistance (IR) and β-cell dysfunction. Islet fibrosis 
promotes the progression of β-cell failure because it 
accelerates β-cell apoptosis [1] and reduces the capacity of 
β-cell proliferation, resulting in a reduced functional β-cell 
mass [2]. Previous studies have shown that the deposition 
of islet amyloid, activation of the renin-angiotensin system 
(RAS) and low-grade chronic inflammation all accelerate 
the development of islet fibrosis [3-5]. The pathogenesis 
of islet fibrosis has not yet been fully clarified, although it 
has been suggested that the activation of pancreatic stellate 
cells (PSCs) is a crucial mechanism initiating islet fibrosis 
in Type 2 diabetes [6]. Our recently research showed 
that PSCs may contribute to the efficient regulation of 
pancreatic development [7], which can be activated to 
proliferate and generate fibrotic extracellular matrix 
(ECM) by a range of environmental stimuli which are 
also associated with T2DM [8]. The process of stellate 
cell activation involves: (i) Proliferation and enlargement. 
(ii) Transformation into a myofibroblast-like phenotype 
and expression of the cytoskeletal marker protein α 
smooth muscle actin (α-SMA). (iii) Decreased expression 
of retinoid- containing fat droplets. (iv) Increased 
responsiveness to cytokines (such as transforming growth 
factor β (TGF-β) and platelet derived growth factor 
(PDGF)). (v) Increased synthesis and secretion of ECM 
components such as collagens and FN. Our recent in vitro 
study showed that a distinct population of islet stellate 
cells (ISCs) could be expanded from isolated islets. 
We observed the dynamic growth of ISCs by Live Cell 
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Station and confirmed that they grew from the inside of 
the islet, rather than spreading from the edge of the islet. 
ISCs had a similar phenotype to PSCs, expressing α-SMA, 
Vimentin, glial fibrillary acidic protein (GFAP), and the 
ECM components, Col-I, Col-III and FN. However, Our 
study also provided evidence that ISCs are not identical 
to classical PSCs in terms of activation, proliferation, 
and motility [9]. Therefore, understanding the roles that 
participate in the process of islet fibrosis is critical for both 
understanding the mechanism and improving treatment of 
diabetes.
The pancreatic Regenerating Protein Product (Reg1) 
was first identified in pancreatic acinar cells, and Reg1 
expression has been implicated in pancreatic cancer [10, 
11], inflammatory bowel disease [12] and autoimmune 
diabetes [13]. Under normal conditions Reg1 is reported to 
be not expressed in rat [14, 15] or mouse [16]islets, but its 
expression is upregulated in mouse islets after induction 
of experimental diabetes with streptozotocin [17], and 
in human islets from patients with T2DM, where Reg1 
expression levels correlate to the duration of diabetes [18]. 
Forced over-expression of Reg1 or the administration of 
exogenous Reg1 induces islet cell proliferation and leads 
to the amelioration of diabetes [19].
Reg1 inhibits PSC proliferation and migration, 
and reduces the synthesis and secretion of Col-I, FN, 
matrix metallopeptidase (MMP)-1 and MMP-2, and the 
tissue inhibitors (TI) of metalloproteinases TIMP-1 and 
TIMP-2 [20]. The putative receptor through which Reg1 
exerts its biological effects has been identified as having 
97% homology with the human multiple EXTL3 [21, 
22], which is highly expressed in mouse islets during 
embryonic development with reduced expression in adult 
islets [23], consistent with a role for Reg1/EXLT3 in β-cell 
expansion and regeneration.
The individual (patho)physiological roles of Reg1/
EXTL3 and PSCs have been investigated extensively 
but little is known about interactions between Reg1 and 
ISCs in the regulation of islet fibrotic responses. In this 
study we have therefore characterized the phenotype of 
ISCs isolated from normal and diabetic mouse islets, and 
investigated the effects of Reg1 on ISC function.
RESULTS
Expression of Reg1 and EXTL3 in pancreas, islets 
and ISCs
Reg1 and EXTL3 protein expression were detectable 
by immunohistochemistry in pancreatic sections, as shown 
in Figure 1A. Pancreas from normoglycemic db/m mice 
showed a few lightly immunostained Reg1+ and EXTL3+ 
cells. In contrast, pancreas from hyperglycemic db/db 
mice contained numerous large, heavily-immunostained 
Reg1+ and EXTL3+ cells throughout the pancreatic tissue. 
Expression of Reg1 and EXTL3 mRNAs and proteins 
was confirmed by qRT-PCR and Western blotting analysis 
using extracts of isolated islets and ISCs from db/db mice 
and db/m mice, as shown in Figure 1B. Both mRNA and 
protein levels of Reg1 and EXTL3 were much lower in 
control db/m islets and ISCs than in the equivalent tissues 
isolated from diabetic db/db mice, in which expression 
levels were much higher (Figure 1B). These observations 
were confirmed by the immunofluorescence microscopy 
measurements shown in Figure 1C, in which both Reg1 
and EXTL3 immunoreactivities were higher in ISCs 
isolated from db/db mice than in ISCs from db/m mice. 
Together these data demonstrate that Reg1 and EXTL3 
are much more highly expressed in pancreatic tissues from 
diabetic mice than from control mice.
Differential activation, migration, viability and 
ECM expression of ISCs isolated from control 
and diabetic mice
Diabetic ISCs had a different function phenotype to 
those isolated from control db/m islets. Thus, the rate of 
ISCs outgrowth was markedly faster from db/db islets and 
db/m islets cultured in high glucose and insulin medium 
when compared to those from db/m mice, as shown in 
Figure 2A, and the rate of activation from the quiescent 
state, as judged by the loss of Red-O stained fat droplets 
(Figure 2B and Supplemental Material S1) was more 
rapid in ISCs isolated from the db/db islets and db/m 
islets cultured in high glucose and insulin medium. We 
used two different in vitro assays - wound healing and 
transwell migration - to compare the migration rates of 
db/m ISCs, db/m ISCs cultured in high glucose and insulin 
medium and db/db ISCs. Both assays showed that db/db 
ISCs and db/m ISCs cultured in high glucose and insulin 
medium had a significantly greater migration rate than 
control db/m ISCs (Figure 2C and Supplemental Material 
S2). Similarly, db/db ISCs had significantly higher rates 
of apoptosis and viability than control db/m ISCs (Figure 
2D), consistent with the enhanced rates of migration and 
activation of the ISCs isolated from the diabetic db/db 
islets.
In accordance with their activation status, ISCs 
isolated from the diabetic mouse islets and db/m ISCs 
cultured in high glucose and insulin medium also 
expressed more α-SMA than control ISCs, as assessed 
by qRT-PCR measurements of elevated levels of 
α-SMA mRNA and Western blotting (Figure 2E) and 
immunohistochemical measurements of α-SMA protein 
(Figure 2E). Similarly, qRT-PCR, Western blotting and 
immunofluorescence microscopy demonstrated that db/db 
ISCs expressed higher levels of Col-I, Col-III and FN than 
control ISCs, as shown in Figure 3A and 3B. Together, 
these data demonstrate that ISCs isolated from a diabetic 
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environment exhibit the characteristics of activated stellate 
cells in terms of migration, viability, ECM deposition and 
activation than ISCs from a normoglycemic environment, 
consistent with ISC activation contributing to the islet 
pathology associated with T2DM. 
Reg1 inhibits the activation of ISCs in db/db 
mouse via its receptor EXTL3
We used shRNA-mediated knockdown of Reg1 and 
EXTL3 expression in db/db ISCs. Exposured to shRNAs 
directed against Reg1 and EXTL3 caused a significant 
reduction in the expression of Reg1 and EXTL3 mRNAs 
by 72 hours when compard to ISCs transfected with 
control non-targeting shRNAs (Supplemental Material 
Figure 1: Expression of Reg1 and EXTL3 in pancreas, islets and ISCs. A. Wax-embedded sections of db/db and db/m mouse 
pancreases showing expression of Reg1 and EXTL3 by immunohistochemistry. Scale bar = 20μm. B. Quantification of Reg1 and EXTL3 
mRNA and protein by qRT-PCR and Western blotting respectively in islets and ISCs. Data are expressed as mean ± SE (n = 3), * P < 0.05, 
** P< 0.01, db/db ISCs compared with db/m ISCs. C. Immunofluorescent staining of ISCs by Reg1 and EXTL3 antibodies (green). Scale 
bar = 20μm.
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Figure 2: The diabetic environment promotes the activation of ISCs. A. Light microscopy micrographs demonstrating faster 
rates of ISC outgrowth from diabetic islets. Scale bar = 50μm. B. Oil red “O” staining of lipid droplets in cytoplasm from ISCs shows faster 
activation and loss of lipid droplets in diabetic ISCs. Scale bar = 50μm. C. Wound healing assay of migration rate shows greater migration 
of diabetic ISCs. Transwell assay of migration rate shows more diabetic ISCs migrating across the filter. Scale bar = 50μm. D. CCK-8 
assay of viability in ISCs. Data are expressed as mean ± SE (n = 15), * P< 0.05, ** P< 0.01. Apoptosis assay of apoptosis in ISCs. Data 
are expressed as mean ± SE (n = 3), * P< 0.05, ** P< 0.01. E. qRT-PCR and Western blotting of α-SMA mRNA and protein expression 
in ISCs. Data are expressed as mean ± SE (n = 3), * P < 0.05, ** P< 0.01. Immunofluorescent staining of ISCs by α-SMA antibody. Scale 
bar = 20μm.
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S3). The knockdown of Reg1 and EXTL3 mRNA was 
maintained and immunoblot analysis confirmed that Reg1 
and EXTL3 protein was also greatly reduced at 72 hours 
post-transfection (Supplemental Material S3). We treated 
islets with rhReg1 to investigate the effects of Reg1 on 
the rate of ISCs outgrowth. The presence of rhReg1 
reduced the rate of ISCs outgrowth from db/m and db/db 
islets were markedly slower when compared to control, as 
shown in Figure 4A.
To investigate the effects of Reg1 on ISC activation 
we treated ISCs with rhReg1, which inhibited their 
activation as assessed by a significantly decreased loss of 
Red-O stained fat droplets (Figure 4B and Supplemental 
Material S4), migration (Figure 4C and Supplemental 
Material S5), viability (Figure 4D), expression of 
α-SMA (Figure 4E) and reduced synthesis and secretion 
of Col-I, Col-III and FN (Figure 4F and Supplemental 
Material S6) with no change in the levels of apoptosis 
(Figure 4D). Conversely, down-regulation of Reg1 
and EXTL3 expression in db/db ISCs by using shRNA 
increased the activation of db/db ISCs, assessed using 
the same parameters (Figure 4C, 4D, 4F). In accordance 
with EXTL3 being the ISC receptor for Reg1, shRNA-
induced down-regulation of EXTL3 abolished the effects 
of exogenous Reg1 to reduce activation of db/db ISCs, 
as shown in Figure 4C, 4D, 4F. Together, these results 
demonstrate that Reg1 inhibits the activation of ISCs via 
its receptor EXTL3.
Figure 3: The diabetic environment enhances ECM expression by ISCs. A. Immunofluorescent staining of ISCs for Col-I, Col-
III and FN. Scale bar = 20μm. B. qRT-PCR and Western blotting measurements of mRNA and protein expression of Col-I, Col-III and FN 
in ISCs. Data are expressed as mean ± SE (n = 3), * P< 0.05, ** P< 0.01, db/db ISCs vs. db/m ISCs.
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Figure 4: Reg1 inhibits the activation of ISCs via its receptor EXTL3. A. Light microscopy micrographs demonstrating rates 
of ISC outgrowth from islets treated with Reg1. Scale bar = 50μm. B. Oil red “O” staining of lipid droplets in cytoplasm from ISCs shows 
slower activation and loss of lipid droplets after treated with Reg1. Scale bar = 50μm. C. Both the wound healing assay and the transwell 
migration assay showed reductions in migration of ISCs treated with rhReg1 (100ng/ml), which was reversed by down-regulation of 
EXTL3. Scale bar = 50μm. D. CCK-8 assay of viability in ISCs treated with rhReg1, sh-Reg1, sh-EXTL3 and sh-EXTL3+rhReg1. Data 
are expressed as mean ± SE (n = 15), * P < 0.05, ** P< 0.01. Apoptosis assay of apoptosis in ISCs. Data are expressed as mean ± SE (n = 
3), * P < 0.05, ** P< 0.01. E. qRT-PCR and Western blotting of α-SMA mRNA and protein expression in ISCs treated with Reg1. Data are 
expressed as mean ± SE (n = 3), * P < 0.05, ** P< 0.01. Immunofluorescent staining of ISCs by α-SMA antibody. Scale bar = 20μm. F. 
Western blotting of db/db ISCs treated with rhReg1, sh-Reg1, sh-EXTL3 and sh-EXTL3+rhReg1 by EXTL3, Col-I, Col-III, FN and TGF-β 
antibody. Data were expressed as mean ± SE (n = 3), * P < 0.05, ** P < 0.01.
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Intracellular mechanism of action of Reg1 in the 
inhibition of ISC activation
To identify potential intracellular signaling 
cascades involved in the Reg1/EXTL3 modulation of 
ISCs activation we used a combination of immunoblot 
and pharmacological inhibitors to identify specific 
signaling elements. Under basal conditions, db/db ISCs 
had higher levels than control ISCs of phosphorylation, 
and thus activation, of Erk1/2, Akt, Smad2/3 and 
reduced expression of Smad7, as shown in Figure 5A. 
Incubation of db/db ISCs with rhReg1, U0126 (Erk 
pathway inhibitor), LY-294002 (PI3K-Akt pathway 
inhibitor), SB431542 (Smad pathway inhibitor) caused 
a significant decrease in phosphorylation of Erk1/2, Akt 
and Smad2/3 (Figure 5B and Supplemental Material S7). 
In contrast, treatment with rhReg1 or the pharmacological 
inhibitors had no effects on total Erk1/2, Akt and Smad2/3 
expression, confirming that the effects observed were 
on the activation of the intracellular signaling pathways. 
Sh-RNA induced down-regulation of Reg1 or EXTL3 
caused small increases in basal phosphorylation of 
Erk1/2, Akt, and Smad2/3 (Figure 5B and Supplemental 
Material S7) but EXTL3 downregulation blocked the 
effects of exogenous rhReg1 to inhibit phosphorylation of 
Erk1/2 and Akt, although the ability of rhReg1 to inhibit 
phosphorylation of Smad2/3 was not blocked by EXTL3 
down-regulation (Figure 5B and Supplemental Material 
S7). Together, these observations suggest that Reg1 acts 
via EXTL3 to inhibit the Erk and Akt pathways in db/
db ISCs, but through another unidentified mechanism to 
influence TGF-β/ Smad pathway activity.
DISCUSSION
Islet fibrosis contributes to the progression of beta 
cell failure by accelerating beta cell destruction in a 
diabetic environment. Emerging evidence indicates that 
the islet fibrosis is attributable to activation of islet stellate 
cells (ISCs).
We have previously reported that isolated 
islets contain a population of stellate cells, which are 
phenotypically similar but not identical to PSCs. In 
common with PSCs these ISCs expressed Vimentin, 
α-SMA and GFAP, and synthesised and secreted the 
ECM components. ISCs differed from PSCs by having 
significantly reduced rates of proliferation and migration 
in vitro. Given the anatomical location of ISCs, and the 
importance of fibrosis in β-cell dysfunction we suggested 
that ISCs maybe contribute significantly to islet fibrosis 
in T2DM. In the current study we have extended these 
observations to show that the functional phenotype of 
ISCs is modified by the diabetic environment in vitro and 
in vivo. This activation of the diabetic ISCs was associated 
with the molecular markers previously identified for PSC 
activation [26], most importantly increased viability and 
migration and the enhanced synthesis and deposition of 
Figure 5: Intracellular mechanism of action of Reg1 in the inhibition of ISC activation. A. Western blotting of ISCs by 
Erk1/2, P-Erk1/2, Akt, P-Akt, Smad2/3, P-Smad2/3, Smad7, TGF-β antibody. Data are expressed as mean ± SE (n = 3), * P < 0.05, ** P < 
0.01. B. Western blotting of db/db ISCs treated with rhReg1, U0126 (10uM), LY-294002 (10uM), SB431542 (10uM), sh-Reg1, sh-EXLT3 
and sh-EXTL3+Reg1 by Erk1/2, P-Erk1/2, Akt, P-Akt, Smad2/3, P-Smad2/3 and Smad7 antibody.
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ECM components, all of which associated with the fibrotic 
response. These observations are consistent with ISCs 
responding to the diabetic environment with increased 
activation potential, leading to islet fibrosis and inhibition 
of normal β-cell function and/or survival. Understanding 
the mechanisms leading to the activation of ISCs in the 
diabetic environment may therefore identify potential 
therapeutic targets to prevent the progression to fibrosis 
in T2DM. 
Our studies have identified the Reg1/EXTL3 
system as one mechanism through which the diabetic 
environment influences ISC function. Reg1 protein is a 
well-known component of pancreatic exocrine juice, and 
was first identified in patients with chronic pancreatitis, 
where it was initially named as human Pancreatic Stone 
Protein (PSP) [27]. PSP was later renamed Pancreatic 
Thread Protein (PTP) [28]and later as pancreatic Reg1 
when it was shown to be expressed in regenerating islet 
cells following a near total pancreatectomy [29, 30]. Reg1 
expression is induced during ductal proliferation, β-cell 
growth and islet regeneration [31, 32], and exogenous 
Reg1 protein has mitogenic effects on ductal cells and 
β-cells [33, 34], reverses diabetes in some animal models 
of β-cell failure [35, 36]. Reg1 expression has also been 
implicated in the islet inflammation and fibrosis associated 
with the development of spontaneous diabetes in GK rats 
[37]and we have previously reported that Reg1 expression 
is significantly up-regulated in patients with T2DM, and 
that Reg1 levels are related to the duration of the TDM 
[18].
In the present study we have shown that Reg1 
and its receptor EXTL3 are expressed in ISCs, albeit at 
a relatively low level under normal conditions, which 
may explain why these Reg1/EXTL3 positive cells 
within islets have not been detected in previous studies 
[14-16]. However, the expression of both molecules is 
highly upregulated in ISCs isolated from diabetic db/
db mice and in db/m ISCs cultured in high glucose 
and insulin medium, demonstrating that the diabetic 
environment increased their expression in ISCs. In 
accordance with this, exogenous Reg1 inhibited the 
activation of db/m ISCs and the shRNA-mediated down-
regulation of endogenous Reg1 in db/db ISCs increased 
their activation, demonstrating that the increased rate of 
activation of the db/db ISCs was caused by the diabetic 
environment regulating the expression of Reg1/EXTL3. 
Thus, exposing ISCs to a hyperglycemic, inflammatory 
pre-diabetic environment leads to upregulation of Reg1/
EXTL3 to maintain them in a quiescent state. With disease 
progression, ISCs produce more Reg1 to protect against 
the hostile environment but the protective effects of Reg1 
becomes overwhelmed, causing the ISCs to become 
activated to a “fibrotic” phenotype and to lay down 
excessive ECM resulting in islet fibrosis. Our observations 
suggest that the Reg1/EXTL3 system exerts a suppressive 
effect on ISC activation, and thus on potential fibrotic 
responses to environmental factors. This conclusion is 
supported by our demonstration that exogenous Reg1 
enhanced EXTL3 expression and reduced the activation 
of db/db ISCs. The effects of Reg1 were mediated through 
EXTL3 because they were abolished when we down-
regulated EXTL3 expression in the db/db ISCs using 
shRNA. Thus, the results of our current study suggest that 
Reg1 acts via EXTL3 suppress activation of ISCs, and 
subsequent islet fibrosis. 
Our study has also provided some insight into the 
intracellular mechanisms through which the Reg1/EXTL3 
system inhibits ISC function. We have demonstrated for the 
first time that Reg1 reduced the phosphorylation and thus 
activation of Akt, Erk1/2 and Smad2/3, which is elevated 
in ISCs as a consequence of the diabetic environment. 
The identification of the Erk, Akt and Smad signaling 
pathways as targets for Reg1 in ISCs is in accordance 
with previous reports in other cell types. For example, 
the PI3K/Akt pathway is associated with cell migration, 
but not proliferation in PSCs [38, 39], consistent with our 
demonstration that the Akt pathway is activated in diabetic 
ISCs, and that exogenous Reg1 can reduce Akt activation 
and diabetic ISC migration. The Erk/MAPK cascade 
is involved in a variety of cellular processes, including 
cell proliferation, cell survival, apoptosis, and cytokine 
production [40], and previous studies have shown that Erk 
activation mediates proliferation and α-SMA expression 
in PSCs [41], consistent with our observations that Reg1 
inhibits phosphorylation and activation of Erk1/2 in db/
db ISCs and that this is associated with their reduced 
viability. It has been reported that rat PSCs exhibited 
increased TGF-β/Smad pathway activity, resulting in 
increased ECM synthesis, increased activation and α-SMA 
expression [42], and Smad2, Smad3, and Smad4 have 
been implicated in PSCs function [43], consistent with our 
demonstration that the TGF-β/Smad pathway is activated 
in diabetic ISCs, Reg1 decrease the expression of ECM 
through inhibition of the TGF-β/Smad pathway, returning 
levels of phospho-Smad2/3 to those of normoglycemic 
ISCs. Although our data demonstrate that EXTL3 is a 
receptor for Reg1 in ISC signaling via the Reg1-EXTL3-
Akt and Reg1-EXTL3-Erk pathways, the effect of EXTL3 
down-regulation on Reg1 signalling via phospho-Smad2/3 
was incomplete, suggesting that Reg1 influences TGF-β/
Smad signaling in ISCs via an additional, and as yet 
unidentified, pathway independent of EXTL3. Although 
these in vitro findings support our hypothesis that Reg1 is 
important for suppression of ISCs activation in a diabetic 
environment further in vivo studies are required, perhaps 
using transgenic models, to confirm the importance of this 
process in the pathogenesis of Type 2 diabetes. 
In summary, we have identified a distinct population 
of stellate cells in islets with a phenotype distinct from 
standard PSCs, and demonstrated that this population of 
ISCs is activated towards a fibrotic phenotype by chronic 
exposure to a diabetic environment, suggesting that these 
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cells participate in the development of islet fibrosis, 
and thus are central to the pathogenesis of T2DM. ISC 
activation is inhibited by Reg1, which acts primarily 
through EXTL3 to prevent diabetes-induced activation of 
the ISC fibrotic phenotype. These studies demonstrate that 
Reg1 can not only promote islet regeneration, but can also 
decrease the activation of ISCs and delay the development 
of islet fibrosis, which may provide new targets for clinical 
drug development to prevent or treat T2DM.
MATERIALS AND METHODS
Animals
The study was reviewed and approved by the 
Animal Care and Use Committee of Southeast University. 
Specific-pathogen-free male C57BL/KsJ-db/db mice 
(aged 8-12 weeks) and age- and sex-matched male lean 
littermate C57BL/KsJ-db/m mice (aged 8-12 weeks) were 
used as controls. All animals were purchased from the 
Model Animal Research Center of Nanjing University 
(Nanjing, China).
Isolation and culture of mouse islet stellate cells
Mouse islets were isolated from db/m and db/db 
mice (12 weeks old and 6 mice each group, the blood 
glucose levels were greater than 13mmol/l) by type IV 
collagenase (1 mg/ml; Sigma, CA, USA) digestion of the 
exocrine pancreas followed by purification on Histopaque 
(Sigma, CA, USA) density gradients. The isolated islets 
were maintained in culture for up to 48 hours at 37°C 
(95% air/5% CO2) [24], with the majority of islets 
attaching to the dish within 3 to 7 days. Cultures were re-
fed when the majority of islets had attached and thereafter 
as needed to replenish nutrients and remove debris. 
“Passage 0” is defined as 10 to 14 days after the islets were 
placed in culture at a time when the cultures were nearly 
confluent with stellate cells. Beginning at passage 0, cells 
were harvested with trypsin and sub-cultured (1:2) every 
3-4 days. Cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM)/Ham’s F12 (1: 1 v/v ) (Sigma, 
CA, USA) containing 10% (v/v) fetal calf serum (FCS) 
and used from passage 3-8. 
Immunohistochemistry
Pancreases (12, 36-week old) were perfused and 
fixed in 4% paraformaldehyde in 0.1 M PBS for 24 hours 
at 4°C, paraffin embedded and sectioned (4 µm). Paraffin-
fixed tissue sections were blocked with 5% bovine 
serum albumin (BSA) for 30 min, incubated overnight 
at 4°C with rabbit anti-mouse Reg1 (1:200, Abcam, 
Cambridge, UK) or rabbit anti-mouse EXTL3 (1:200, 
Santacruz, Dallas, USA), then washed and incubated 
with HRP-linked anti-rabbit serum at room temperature 
for 30 min. The sections were then developed with DAB, 
counterstained with hematoxylin, and examined using an 
Olympus BX40 microscope.
Immunofluorescence Microscopy of Reg1, 
EXTL3, α-SMA, FN, Col-I and Col-III
Immunofluorescence microscopy was performed as 
described previously [9] to evaluate differences between 
ISCs isolated from db/m and db/db mice in the expression 
of Reg1, EXTL3, α-SMA, FN, Col-I and Col-III (1:200, 
Abcam, Cambridge, UK). All immunocytochemical 
analyses were performed in triplicate.
Oil red O staining
Islets and ISCs were either cultured alone, or in 
medium supplemented with D-glucose (25mmol/l) and 
insulin (100nM) (high glucose and insulin medium), or 
with rhReg1 (100ng/ml) for 24 hours unless otherwise 
specified. Oil Red O Staining (Sigma, CA, USA) was 
performed as described previously [9].
Determination of cell viability
Cell viability was assessed directly by WST-8 assay 
(Sigma, CA, USA)as described previously [9]. ISCs were 
either cultured for alone, or with D-glucose and insulin 
(high glucose and insulin medium), or with shRNA, or 
with rhReg1 for 24 hours unless otherwise specified. 
All experiments were performed in quintuplicate on 
three separate occasions (n = 15). Three independent 
experiments were performed in triplicate.
Detection of cell migration
Wound healing
ISCs were seeded in 6-well culture plates and grown 
for 24 hours to reach confluence. ISCs were cultured as 
described above. After starvation with serum-free medium 
overnight, Then wound healing assay was performed as 
described previously [9].
Transwell assay
ISCs were seeded in transwells (BD 353097, 8 mm 
pores), ISCs were cultured as described above and the 
transwell assay was performed as described previously [9].
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Apoptosis assay
An annexin V-fluorescein isothiocyanate (FITC)/
propidium iodide (PI) apoptosis detection kit was used to 
analyze cell apoptosis as described previously [9].
Quantitative real-time polymerase chain reaction 
(qRT- PCR)
ISCs were seeded into Nunclon™ 35mm petri 
dishes, and either cultured alone, or with high glucose 
and insulin medium, or with shRNA, or with rhReg1 for 
24 hours unless otherwise specified. After 24 hours, total 
RNA was extracted from ISCs using TRIzol (Invitrogen, 
NY, USA), and 1 μg of total RNA was reverse transcribed 
into first-strand cDNA by using a reverse transcription 
reagent kit (TaKaRa BIO, Otsu, Japan) according to the 
manufacturer’s protocol. qRT-PCR was performed using 
the SYBR® Green real-time PCR kit (TaKaRa BIO, Otsu, 
Japan). qRT-PCR was performed on the ABI StepOnePlus 
Real-Time PCR system (Applied Bio-systems, Foster City, 
CA, USA). All quantifications were performed with U6 as 
the internal standard. The PCR primer sequences were as 
follows: 
Reg1, 5’-TAACAGTTCCAATCGTGGCTAC -3’ 
(sense) and 5’-
GGGCATCACAGTTCTCATCCT -3’ (antisense); 
EXTL3, 5’-TGCCCTGGAATGAGATAGAGAC 
-3’ (sense) and 5’-TGATGTGGGAGACAAGGAAGTT 
-3’ (antisense); 
α-SMA, 5’-CAGCAAACAGGAATACGACGAA 
-3’ (sense) and 5’-AACCACGAGTAACAAATCAAAGC 
-3’ (antisense); 
FN, 5’- GCAAGAAGGACAACCGAGGAAA -3’ 
(sense) and 5’-GGACAGCAGTGAAGGAGCCAGA -3’ 
(antisense); 
Col-I, 5’-GTCAGACCTGTGTGTTCCCTACTCA 
-3’ (sense) and 5’-TCTCTCCAAACCAGACGTGCTTC 
-3’ (antisense); 
Col-III, 5’-GGACCAGGCAATGATGGAAAAC 
-3’ (sense) and 5’-GGACCAGGGAAACCCATGACA -3’ 
(antisense); 
β-actin, 5’-GAGAGGGAAATCGTGCGTGACA 
-3’ (sense) and 5’-ACCCAAGAAGGAAGGCTGGAAA 
-3’(antisense). 
Relative gene expression was analyzed using 
the 2-ΔΔCT method, and the results were expressed as 
extent of change with respect to control values. qRT-PCR 
experiments were replicated at least 3 times.
Western blotting analysis 
 ISCs were seeded into Nunclon™ 35mm petri 
dishes and either cultured alone, or in the presence of 
shRNA, or rhReg1, or U0126 (10µM, Sigma, CA, USA), 
or LY294002 (10µM, Sigma, CA, USA), or SB431542 
(10µM, Selleck, Houston, USA) for 24 hours unless 
otherwise specified. After 24 hours, ISCs were lysed 
with ice-cold lysis buffer supplemented with protease 
inhibitors (Roche, Basel, Switzerland). After protein 
content determination and separation with 12%(w/v) 
SDS-PAGE, Western blotting was performed, as described 
previously [25], using antibody against primary antibody 
in 2.5% non-fat dried milk in Tris-buffered saline with 
Tween-20 (TBST) buffer. The primary antibody were as 
follows: Reg1 (1:3000, Abcam, Cambridge, UK), EXTL3 
(1:200, Santacruz, Dallas, USA), α-SMA (1:1000, Abcam, 
Cambridge, UK), Col-I (1:5000, Abcam, Cambridge, UK), 
Col-III (1:5000, Abcam, Cambridge, UK), FN (1:5000, 
Abcam, Cambridge, UK), TGF-β, Akt, P-Akt, Erk, P-Erk, 
Smad2/3, P-Smad2/3, Smad7 (1:1000, Cell Signaling, 
MA, USA), β-Actin (1:2000, Sigma, CA, USA).
shRNA preparation and targeting gene 
knockdown
Specific shRNAs and control shRNA were designed 
and synthesised by HANBIO (Shanghai, China). Blast 
search was performed with the National Center for 
Biotechnology Information (NCBI) database to ensure that 
the shRNA constructs were targeting only mouse Reg1 or 
EXTL3. The oligonucleotides were annealed and cloned 
into the pHBLV-U6-ZsGreen-Puro as the manufacturer 
described. 10μg of pHBLV-U6-ZsGreen-Puro constructs 
containing shRNAs, 10μg of packaging plasmid psPAX2 
(Addgene), and 10μg of envelope plasmid pMD2.G 
(Addgene) were used to transfect HEK293T cells by 
the calcium phosphate precipitation method. After 48 
hours lentiviruses containing targeted gene shRNA were 
collected and used to transfect ISCs according to the 
manufacturer’s instructions.
Statistical analysis
Quantitative data were expressed as mean±SEM. 
The statistical significance was determined by analysis 
of variance followed by Bonferroni’s T test for multiple 
comparisons, and differences were considered significant 
when P < 0.05.
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